{"id":755831,"date":"2023-05-08T07:34:02","date_gmt":"2023-05-08T11:34:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/"},"modified":"2023-05-08T07:34:02","modified_gmt":"2023-05-08T11:34:02","slug":"marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/","title":{"rendered":"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer"},"content":{"rendered":"

\nAccomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Therapeutics
\n<\/h2>\n
\n

HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc.<\/a> (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen (multiTAA)-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical study of MT-601.<\/p>\n

\u201cAs we undergo a strategic review of our clinical programs, we are thrilled to add Monic to the leadership team at Marker Therapeutics and look forward to benefitting from her deep scientific, industry, and medical knowledge to drive our multiTAA-specific T cell product pipeline across multiple high-need cancer indications,\u201d said Juan F. Vera, M.D., Chief Executive Officer of Marker Therapeutics. \u201cGiven Marker\u2019s prioritization of the clinical program in acute myeloid leukemia (AML) and lymphoma, bringing on a CMO who is a transplant physician and has extensive experience in treating AML and lymphoma patients is a tremendous advantage in establishing our clinical strategy. Dr. Stuart\u2019s impressive career both in industry and in the clinic as a treating physician will be key to enabling Marker to identify the optimal paths for advancing our programs targeting hematologic and solid tumors.\u201d<\/p>\n

Dr. Stuart joins Marker Therapeutics as a consultant after having most recently worked as interim Chief Medical Officer, Head of Clinical Development or Clinical Advisor for numerous biotechnology and pharmaceutical companies worldwide. In this capacity, Dr. Stuart was responsible for leading each company\u2019s clinical strategy including clinical development plans, Phase 1-3 study designs, and protocol development for a variety of benign and malignant hematologic, solid tumor, and supportive care indications. Dr. Stuart previously served as Vice President of Clinical Development at Geron Corporation, where she spearheaded efforts to develop a telomerase inhibitor in myeloid malignancies. Before her role at Geron Corp., she worked at Genentech Inc. as a Senior Medical Director in the Oncology Division. During her time at Genentech, she served in leadership position for multiple early and late-stage hematology\/oncology programs.<\/p>\n

Prior to Genentech, Dr. Stuart served as an attending physician in the Division of Blood and Marrow Transplantation at Stanford University, where she led trials in myeloid malignancies. Dr. Stuart received her M.D and B.S. in Biology from the University of North Carolina at Chapel Hill. She completed her medical residency in internal medicine and fellowships in hematology and bone marrow transplantation at Stanford University. Dr. Stuart also holds a Master\u2019s Degree from the School of Public Health at Johns Hopkins University.<\/p>\n

\u201cMarker’s unique T cell-based immunotherapies have the potential to transform the treatment of cancer, and I am excited to work with the team to advance the development of these promising therapies,\u201d said Dr. Stuart. \u201cImportantly, the Company\u2019s MT-401 Phase 2 ARTEMIS clinical trial continues to advance with recent data suggesting MT-401 manufactured with the improved T cell manufacturing process would be well suited for AML patients. I am intrigued by this potential as well as the opportunity to advance our MT-601 program in non-Hodgkin lymphoma and pancreatic cancer.\u201d<\/p>\n

\n About Marker Therapeutics, Inc.<\/strong>
\n
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The cell therapy technology Marker has is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient\u2019s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.<\/p>\n

To receive future press releases via email, please visit: https:\/\/www.markertherapeutics.com\/email-alerts<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company\u2019s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are \u201cforward-looking statements.\u201d Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct and success of our clinical trials of our product candidates. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company\u2019s most recent Form 10-K, 10-Q and other\u00a0SEC\u00a0filings which are available through EDGAR at\u00a0WWW.SEC.GOV<\/a>. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n

\n
\n Contacts<\/u>
\n <\/strong>
\n
\n
\n TIBEREND STRATEGIC ADVISORS, INC.<\/strong>
\n <\/a>
\n
\n Investors<\/strong>
\n
Daniel Kontoh-Boateng
(862) 213-1398
dboateng@tiberend.com<\/a><\/p>\n

\n Media<\/strong>
\n
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Accomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Therapeutics HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen (multiTAA)-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical study of MT-601. \u201cAs we undergo a … <\/p>\n

Continue reading “Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755831","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMarker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Accomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Therapeutics HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen (multiTAA)-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical study of MT-601. \u201cAs we undergo a … Continue reading "Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T11:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer\",\"datePublished\":\"2023-05-08T11:34:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/\"},\"wordCount\":990,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/\",\"name\":\"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=\",\"datePublished\":\"2023-05-08T11:34:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Market Newsdesk","og_description":"Accomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Therapeutics HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen (multiTAA)-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical study of MT-601. \u201cAs we undergo a … Continue reading \"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-08T11:34:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer","datePublished":"2023-05-08T11:34:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/"},"wordCount":990,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/","name":"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=","datePublished":"2023-05-08T11:34:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzU5NiM1NTc5NTQ5IzIxODc3MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755831"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755831\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}